




Daniel Jünemann (Autor)

Analytics of dissolution testing of products containing nanosized drugs with a view to predicting plasma profiles

Daniel Jünemann

Analytics of dissolution testing of products containing nanosized drugs with a view to predicting plasma profiles



Cuvillier Verlag Göttingen
Internationaler wissenschaftlicher Fachverlag

<https://cuvillier.de/de/shop/publications/115>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentzsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany

Telefon: +49 (0)551 54724-0, E-Mail: info@cuvillier.de, Website: <https://cuvillier.de>

Table of contents:

1	Introduction	1
1.1	<i>Oral bioavailability</i>	1
1.2	<i>Factors limiting oral bioavailability</i>	2
1.3	<i>Solubility and drug dissolution</i>	3
1.4	<i>The biopharmaceutics classification system</i>	5
1.5	<i>Formulation of poorly soluble substances</i>	8
1.6	<i>Particle size reduction in pharmaceutical technology</i>	13
1.6.1	<i>Particle size reduction</i>	14
1.6.2	<i>Dry milling methods</i>	16
1.6.3	<i>Wet milling methods</i>	17
1.6.4	<i>Comparison of dry and wet milling techniques</i>	17
1.6.5	<i>Combining micronization with other techniques</i>	18
1.7	<i>Rationale for nanonization of drug particles</i>	19
1.8	<i>Preparation of nanosized drug particles</i>	20
1.8.1	<i>Wet-milling methods (bead mills)</i>	21
1.8.2	<i>High pressure homogenization</i>	23
1.8.3	<i>Commercialized nanosized drugs</i>	24
1.8.4	<i>Increase of bioavailability by nanonization</i>	25
1.8.5	<i>The lack of food effects using nanosized APIs</i>	27
1.8.6	<i>Improvement of bioavailability for drugs with an absorption window</i>	28
1.9	<i>Sample preparation and analysis in dissolution testing</i>	29
1.9.1	<i>HPLC-UV</i>	30
1.9.1.1	<i>The use of syringe filter</i>	30
1.9.1.2	<i>Centrifugal filter devices</i>	31
1.9.1.3	<i>Dialysis methods</i>	31
1.9.1.4	<i>Microdialysis</i>	32
1.9.2	<i>Fiber optics</i>	32
1.9.3	<i>Turbidity measurement</i>	34
1.9.4	<i>ResoScan</i>	35
1.9.5	<i>Asymmetrical flow - field-flow fractionation</i>	35
1.9.6	<i>Ion-selective electrode</i>	37
2	Aims of thesis	39
2.1	<i>Evaluation of the use of an ion-selective electrode system in biorelevant dissolution testing using diphenhydramine HCl as model drug</i>	39

2.2	<i>Evaluation of the ion-selective electrode as potential tool for analysis of supersaturated systems</i>	39
2.3	<i>Evaluation of analytical methods in dissolution testing of nanosized fenofibrate</i>	40
2.4	<i>Establishment of an in vitro - in vivo - correlation for a nanosized drug using an in silico simulation approach</i>	40
3	Materials and Methods	41
3.1	<i>Materials</i>	41
3.1.1	<i>Chemicals</i>	41
3.1.2	<i>Model substance diphenhydramine HCl</i>	43
3.1.3	<i>Model substance fenofibrate</i>	44
3.2	<i>Methods.....</i>	46
3.2.1	<i>Case example of particle size reduction: fenofibrate</i>	46
3.2.2	<i>Dissolution studies.....</i>	48
3.2.3	<i>Composition of dissolution media.....</i>	49
3.2.4	<i>Syringe filters</i>	50
3.2.5	<i>Microdialysis system.....</i>	51
3.2.6	<i>Centrifugal filter devices.....</i>	51
3.2.7	<i>High performance liquid chromatography (HPLC-UV) used for assays.....</i>	52
3.2.8	<i>ResoScan system.....</i>	53
3.2.9	<i>Analyses of in vitro data.....</i>	54
3.2.9.1	<i>Model independent f_1- and f_2- factor calculation.....</i>	54
3.3	<i>Special methods for diphenhydramine HCl</i>	54
3.3.1	<i>Filter adsorption studies for diphenhydramine HCl.....</i>	54
3.3.2	<i>Dynamic light scattering</i>	55
3.3.3	<i>The ion-selective electrode.....</i>	55
3.3.4	<i>Calibration of the ion-selective electrode for diphenhydramine HCl.....</i>	56
3.3.5	<i>Dissolution testing</i>	57
3.3.6	<i>Endpoint calibration via ISE (method A)</i>	57
3.3.7	<i>Endpoint calibration via HPLC-UV (method B).....</i>	58
3.3.8	<i>Adaption of Method B for measurement of poorly soluble substances</i>	58
3.3.9	<i>Analysis of significance using ANOVA.....</i>	58
3.4	<i>Special methods for fenofibrate:</i>	59
3.4.1	<i>Filter adsorption studies for fenofibrate.....</i>	59
3.4.2	<i>Analysis of in vivo pharmacokinetic data</i>	59
3.4.3	<i>Computer simulation of fenofibric acid plasma profiles</i>	60
3.4.3.1	<i>The STELLA® model</i>	60

3.4.3.2	<i>Calculation of z-value</i>	66
3.4.3.3	<i>Adaption of original model for permeability restrictions</i>	67
3.4.4	<i>Comparison of simulated plasma profiles to in vivo data</i>	68
3.4.5	<i>Sensitivity analyses</i>	69
4	Results and discussion	70
4.1	<i>Discussion of methods evaluated for in situ measurement of the analyte in the dissolution test</i>	70
4.2	<i>ResoScan</i>	71
4.3	<i>Microdialysis</i>	72
4.4	<i>Centrifugal filter devices</i>	73
4.1	<i>Ion-selective electrode</i>	75
4.1.1	<i>Filter adsorption studies</i>	75
4.1.2	<i>FaSSGF</i>	75
4.1.3	<i>FaSSIF</i>	77
4.1.4	<i>FaSSIF-V2</i>	82
4.1.5	<i>FeSSGF</i>	84
4.1.6	<i>FeSSIF / FeSSIF-V2</i>	86
4.1.7	<i>Evaluation of potential use of the ISE for nanosized drugs</i>	88
4.2	<i>Fenofibrate</i>	91
4.2.1	<i>Filter adsorption studies</i>	91
4.2.2	<i>Solubility studies</i>	94
4.2.3	<i>Dissolution in FaSSIF and FeSSIF using various filter pore sizes</i>	95
4.3	<i>Theoretical increase of dissolution rate by particle size reduction</i>	99
4.4	<i>Comparison of dissolution rate in theory and in practice</i>	102
4.5	<i>Evaluation of the STELLA[®] software to generate simulated plasma profiles</i>	103
4.6	<i>Discussion of the conventional approach vs. a new method for rapidly dissolving compounds</i>	105
4.7	<i>Calculation of z-values</i>	109
4.8	<i>Simulated plasma profiles of fenofibric acid Model A</i>	110
4.8.1	<i>Sensitivity analyses model A</i>	111
4.8.1.1	<i>Influence of gastric emptying rate</i>	111
4.8.1.2	<i>Influence of gastric dissolution rate</i>	114
4.8.1.3	<i>Influence of intestinal dissolution rate</i>	116
4.9	<i>Simulated plasma profiles of fenofibric acid model B</i>	118
4.9.1	<i>Sensitivity analyses Model B</i>	119
4.9.1.1	<i>Influence of intestinal dissolution in the fasted state</i>	120



4.9.1.2	<i>Influence of gastric emptying rate in the fed state</i>	121
4.9.1.3	<i>Influence of permeation rate across the intestinal mucosa</i>	122
4.9.2	<i>Discussion of STELLA[®] software</i>	123
4.9.2.1	<i>Possible applications using the presented model in STELLA[®]</i>	124
4.9.2.2	<i>Limitations of the STELLA[®] model</i>	125
5	General discussion of thesis	126
6	Outlook	133
6.1	<i>Studies regarding the ISE</i>	133
6.2	<i>Filter adsorption testing</i>	133
6.3	<i>Establishment of an in vitro - in vivo - correlation for a nanosized drug</i>	134
7	Summary	135
8	Appendix	141
9	References	166
10	Summary (German)	173
11	Curriculum vitae	179